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Abstract 
Heart disease is the leading cause of death in the United States, leaving the afflicted with lost or 
damaged cardiac tissue.  Cardiac patches can be used to repair or replace this tissue.  Current methods 
include using synthetic and extra cellular matrix patches.  Completely cell-derived patches seek to 
improve on current methods, but the production processes are time-consuming and labor-intensive.  
The goal of this project was to design a bioreactor to address these problems by generating multiple 
totally cell-derived patches quickly, consistently, and with minimal effort.   A bioreactor was designed 
that allows the production of tissue patches without user intervention. The device contains a volume of 
media sufficient for extended culture periods to feed the cells.  A controllable media distributor 
circulates media throughout the system that has the ability to generate up to 12 tissue patches per trial. 
This also allows multiple culture materials to be tested at once, depending on the needs of the user. This 
automated versatile device fits in a tissue culture incubator and is compatible with a variety of human 
cell types for clinical and experimental use.   
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1 Introduction 
Heart disease is the leading cause of death for both men and women in the United States.  
There are several diseases that can lead to loss or damage to myocardial tissue.  Three of these diseases 
are myocardial infarction (MI), hypertrophic cardiomyopathy and congenital defects.    These diseases 
are prevalent; there are 565,000 new cases of MI annually, one in 500 individuals suffers from 
hypertrophic cardiomyopathy, and 650,000 to 1,300,000 people in the United States are born with 
congenital cardiovascular defects.  (American Heart Association, 2008) 
Patches can be used to repair these defects and restore the natural shape of the heart.  
Synthetic patches such as Dacron and polytetrafluoroethylene (PTFE), or extracellular matrix (ECM) 
patches can be used.  There are a number of disadvantages associated with each of these patch types.  
Synthetic patches are much stiffer than natural heart tissue; the modulus of elasticity is at least 4 orders 
of magnitude greater than natural myocardium.  Because of this a Dacron patch would “tether” the 
heart muscle and reduce the mechanical function of the surrounding myocardium. This can reduce both 
diastolic and systolic function. (Kochupura, 2005) In pediatric patients, these patches are unable to grow 
with the patient, and additional surgeries are required.  (Leor, 2005) ECM patches are comprised of 
decellularized tissue, often from non-human sources.  Complications with these patches can include 
calcification and inflammatory response (Kofidis, 2002)  
Patches that are totally cell-derived would solve many problems associated with current 
patches.  These patches would have the same mechanical properties (ultimate tensile strength, 
compliance etc.) as the original tissue (Leor, 2005), could potentially be grown from the patient’s own 
cells, would be biocompatible, and would eliminate rejection.   
Unfortunately, producing these cellular patches is challenging.  The sheets can be cultured in a 
flask, but this method can take up to 30 days. (L'Heureux, 1998) Other culture methods have been 
researched that allow the patch to be easily removed from the culture surface.   Unfortunately, the cell 
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sheets cultured with this method are only one cell thick and multiple sheets must be layered on top of 
each other to create a sufficiently thick patch.  This is a time-consuming and labor-intensive task.  
(Shimizu, 2002) A bioreactor has the potential to reduce culture time and produce thicker cellular 
sheets. 
The goal of this project was to produce stable, totally cell-derived tissue patches, quickly and 
consistently.  The primary objectives were to: provide automated nutrient delivery, develop 
reproducible results, allow for easy cell sheet removal, produce high throughput patch generation, and 
be easy to use.  The bioreactor needed to perform the following functions: generate a cell sheet, seed 
cells, feed cells, easily release the resulting patch, and allow for user monitoring.  The specifications 
were that the bioreactor must: generate a cell sheet that is at least 15 mm in diameter, fit in a standard 
incubator, and produce more than five samples per trial.   
In order for the bioreactor to perform these functions, means for both the patch and the 
bioreactor were determined.  To grow cells into a patch, a support that allows and encourages cell self-
assembly is necessary. After a review of literature, two different options were decided upon: Transwells 
and Nitex/polyethylene constructs.  Transwells are individual culture columns with porous membranes 
at the bottom that trap cells inside the column while allowing the passage of media through the filter.  
The Nitex are similar to Transwells, in that they contain a filter material for cell culture, while allowing 
the passage of media.  Additionally, the Nitex mesh is adhered to porous polypropylene rings that 
anchor the cells, and include a fibrin gel that acts as a temporary surface, assisting with and encouraging 
cell attachment and allowing for easier removal of the resulting sheet.  Both are accepted cell culture 
materials were chosen to meet these criteria.   
The final design consists of a base which acts as a media reservoir, inserts to hold the chosen 
culture materials, and a lid which includes a flow distribution system.  All of these components were 
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machined of polycarbonate.  The base is designed to hold enough media to support cell life for an 
extended period of time (greater than one week), and fit within the incubator.   
The lid acts as an irrigation system, containing troughs that distribute the media to each sample.  
The media is circulated from the reservoir in the base to the lid with a peristaltic pump.   
This bioreactor has the ability to culture cell sheets for prolonged periods of time without user 
intervention. It can be used to test multiple culture materials in one period or produce up to twelve 
samples per trial. Overall it will provide a method to generate a high number of tissue sheets with 
minimum effort by the user. 
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2 Literature Review 
2.1 Heart Disease 
 Cardiovascular disease (CVD) is any disease or defect that affects heart or blood cell function; 
more than 80 million adults are diagnosed with a form of CVD.  Heart disease is the leading cause of 
death in the United States as nearly 2400 Americans die from it each year.  (American Heart Association, 
2008)  Common symptoms include chest pain (angina), shortness of breath, and pale grey skin. The most 
common form is myocardial infarction (heart attack) and these occur in 8,100,000 American adults.  
Also, a significant number of people, 650,000-1,300,000 in the United States, are born with a congenital 
cardiovascular defect. (American Heart Association, 2008) Treatment options vary depending on the 
type of CVD that the patient is diagnosed with.  
 Myocardial infarction occurs when a blockage develops in a coronary artery, preventing the 
blood from adequately being supplied to the myocardium. Without the necessary oxygen or nutrients to 
survive, myocytes enter a state known as ischemia, and begin to die. This can lead to a heart attack and 
progressive heart failure as the heart muscle is not longer able to function. The heart is incapable of self 
regeneration therefore medical intervention is necessary. (Leor, 2005)  If the heart is significantly 
damaged and life style changes and medication are ineffective, a standard method is to replace the 
heart tissue, either with a tissue engineered cardiac patch or a complete heart transplant (American 
Heart Association, 2008) (Atkins, 2002). 
An approach to cardiovascular repair involves the implantation of a cardiac patch. An example 
of this type of procedure is the Endoventricular Circular Patch Plasty or the DOR procedure. This method 
removes the damaged portions of the anterior wall and septum of the heart. The left ventricle is then 
reshaped using sutures and a synthetic patch is implanted on the ventricular wall. (Sartipy, 2005) The 
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primary the goal of these patches is to simply restore the natural shape of the heart, and to repair the 
continuity of the ventricular wall.    
Congenital defects also often require surgery to render improved cardiac function. 
Approximately 28.3 % of ventricular septal defects (a congenital birth deficiency) could also be treated 
with a vascular patch. (Kofodis, 2002) Currently, clinically available patches are composed of synthetic 
materials such as expanded polytetrafluoroethylene (ePTFE), or polyethylene terephthalate (PET).  
Another category of patches utilizes extracellular matrix (ECM) as their basis. These vascular patches are 
derived from porcine small intestinal submucosa and urinary bladder matrix (UBM), and have 
undergone preclinical experimentation as vascular grafts. (Robinson, 2005)   
Synthetic patches do not promote native cell in-growth.   Instead they incite biological reactions 
including inflammatory response (Kofidis, 2002) and scar tissue formation. (Robinson, 2005) Both of 
these results are not ideal for improved heart function.   The natural material that is currently used is 
treated bovine pericardium and utilizing animal products in human treatments is also less than ideal.   A 
patch that promoted cell in-growth and was totally cell-derived could be the perfect substitute for 
natural human tissue.  
2.2 Cardiac Patches 
There is a considerable need for implantable cardiac patches that could replace damaged heart 
tissue.  The patch must be biologically and functionally comparable to native heart tissue.  Scaffolds are 
often utilized to achieve such patches.       
 Synthetic scaffolds that have been approved for clinical use in the United States include 
expanded Polyethylene terephthalate (PET) and Polytetra-Fluoroethylene (ePTFE), commonly known as 
Dacron and Teflon.    Both Gore Medical Products and Bard Peripheral Vascular produce commercially 
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available ePTFE patches.   Bard Peripheral Vascular and Boston Scientific produce PET cardiac patches.  
Commercially available patches are shown below in Table 1. 
 
Table 1 - Commercially Available Patches 
 
(Filipe, 2007) 
Dacron and Teflon patches do not degrade and their synthetic origin induces a thick layer of scar 
tissue around the implant, reducing ventricular contraction.    Dacron patches have been seeded with 
cells to provide a regenerative scaffold environment and achieve better integration with the 
surrounding tissue.    However, the differences in mechanical properties between the patch and natural 
heart tissue remain a significant issue.  (Gaudette, 2006) 
  Tissue constructs consisting entirely of cell-derived matrix are best suited for implantation 
because they are biologically and functionally comparable to native tissue.    (L'Heureux, 1998) Research 
has recently focused on generating tissue constructs based on the use of cultured human cells without 
any synthetic or exogenous biomaterials.  This research utilizes the tendency of dermal fibroblasts to 
self assemble and produce a sheet when cultured with ascorbic acid.    Ascorbic acid treatment is also 
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used during culture since it stimulates collagen production, and improves mechanical properties such as 
stiffness.  (L'Heureux, 2007)  
The most significant constraint of cell-derived patches is the time it takes for the cells to 
produce matrix and self-assemble into a sheet.  Many factors can be optimized to reduce the production 
time: initial cell concentration, culture medium components, and media selection.    (L'Heureux, 1998)  A 
method to decrease culture and maturation period is through the use of an appropriate bioreactor 
which could generate a compliant scaffold to replace the infracted heart tissue. (Martin, 2004)    In this 
instance, compliance is referring to mechanical properties, specifically the material’s ability to withstand 
the stresses and strains placed on the heart during normal function.  (Arrigoni, 2008)  It is accepted that 
static culture is not sufficient to produce tissue that is adequately functional in terms of cell 
proliferation, cell differentiation, ECM production and tissue organization. (Arrigoni, 2008) Bioreactors 
seek to address this issue by more closely mimicking the natural environment than static culture.   
2.3 Bioreactors 
 Producing tissue engineered substances can be difficult and costly; therefore devices have been 
developed to aid this process.    Bioreactors are devices that control environmental and operating 
conditions to aid biological and biochemical mechanisms such as cellular alignment and ECM 
production. (Zhao, 2004)    These devices allow experimental variable control and increased production 
capabilities.    Currently in tissue engineering it is common to utilize a scaffold material in a bioreactor as 
a surface for seeding cells.  
 The seeding process in a bioreactor is critical.    The cell distribution can have significant effects 
on the properties of the engineered material.  (Martin, 2004) This provides a significant challenge, and 
multiple methods have been developed to address it.    Statically seeding or manually placing the cells in 
the media is a common and fairly simple method, but it has several disadvantages.    Studies have shown 
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that this method exhibits low seeding efficiencies onto scaffolds due to user error and inconsistencies 
(Martin, 2004).   Another approach to seeding involves a stirred flask bioreactor in which cells 
suspended in media surround a stationary scaffold.    Unfortunately, this method does not allow uniform 
cell seeding between the surface and the interior of the scaffold. (Martin, 2004)    To seed the interior of 
a surface, cells and media can be directed through the scaffold.    This final method is referred to as 
perfusion seeding. (Martin, 2004)    
The basic method of culturing cells culture is static culture but, while it is effective, it is very 
limited.  Nutrient and oxygen delivery is limited by diffusion; any cells outside of this diffusion range 
become apoptotic.    Apoptosis is when cells are unhealthy or problematic, and self destruct.    Static 
culture also does not realistically mimic the mechanical in vivo environment.    In vivo, the construct is 
subjected to forces such as: shear force, compressive stress and tensile stresses.    These forces affect 
tissue growth, and ideally they should be replicated in vitro.    Bioreactors can help solve these issues by 
utilizing dynamic cell culture methods, such as perfusion or rotation.  (Martin, 2004) 
Perfusion cell culture involves the cell media being forced to flow through the tissue culture 
chamber.    This flow can create excessive shear forces that are detrimental to cells in a tissue culture 
environment.    To address this, the flow rate must be carefully calculated.    (Martin, 2004)   Studies 
have shown that perfusion bioreactors can enhance a variety of factors including growth and 
differentiation, and can deliver a significantly larger cell density than other static methods. (Martin, 
2004)    Another advantage of a perfusion bioreactor is that cell seeding and nutrient delivery systems 
can become automated.  (Martin, 2004)    This removes inconsistencies associated with human error, 
but has the additional concern of potential mechanical failure.    Automated systems are also adaptable 
for multiple, independent samples.    This involves multiple chambers to allow the growth of several 
engineered tissue constructs in a single experiment.  (Zhao, 2005)     
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 A rotating bioreactor is another alternative.    This type of bioreactor involves a cellularized 
construct that is immersed in culture medium, and placed in a rotating chamber. (Arrigoni, 2008)    The 
theory of this device class is that it allows a more uniform oxygenation of the cells than static seeding, 
but applies significantly lower levels of shear stress than a perfusion bioreactor.    It is also mechanically 
simpler than a perfusion bioreactor, which can be advantageous in a research environment (Arrigoni, 
2008).    Media delivery is typically not automated, but can be achieved using a simple pipette media 
exchange method.  
While current bioreactors have improved cell culture techniques there are still limitations. They 
are labor intensive, have long culture periods, and are expensive.  Bioreactors commonly use a scaffold 
to seed cells onto.   A bioreactor that is easy to use has a shorter culture time, and produces totally cell-
derived sheets. 
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3 Project Strategy 
 Initially the team received the following client statement: 
Self-assembled cell sheets have been used to fabricate a variety of engineered tissues, including vascular 
grafts and patches for cardiac repair.   One of the limitations of this approach is the amount of time 
required to culture sheets of sufficient mechanical integrity for manipulation and transplantation.   The 
goal of this project is to design a novel bioreactor system to rapidly and reproducibly fabricate and 
culture mechanically stable cell-derived tissue sheets.    
 Before the team could formulate a design, an iterative design process was followed.   First the 
stakeholders were identified.   From these stakeholders, the project objectives, specifications, 
constraints, and functions were formulated.   These criteria are critical to ensuring that the designed 
product meets the client’s needs thoroughly.   It also establishes the parameters in which the design 
must stay.   From these criteria, a new client statement was formed and provided the basis upon which 
the design alternatives were formed. 
3.1 Stakeholders 
 The stakeholders were defined as the clients, the designers, and the users as shown in Figure 1. 
 
Figure 1: Project Stakeholders 
Designers:
•MQP Team
Users:
•Project Advisor
•Graduate Students
Clients:
• Project Advisor
• GraduateStudents
• Cardiovascular surgeons
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 The main stakeholders in this project were Dr. Marsha Rolle and the design team.   These 
individuals determined the objectives and functions of the new bioreactor and the tissue sheet output.    
 The primary users of this bioreactor and its tissue sheet products will be Dr. Marsha Rolle and 
the graduate students working in her lab.   Their main concern was that they needed a method to create 
a cell sheet patch with adequate mechanical properties quickly and easily.    
 The clients that were considered were the same group as the users.   Eventually the clients of 
this patch may extend to cardiac surgeons implanting the patch in patients, but that is currently beyond 
the scope of this design project. 
3.2 Objectives 
 Based on the feedback from the stakeholders of this project and conducted research, the team 
generated design objectives to guide the design process.   The main level objectives and secondary level 
objectives are listed below. 
Objectives 
 Automated Nutrient Exchange 
 Reproducible 
o Mechanical Properties 
o Sheet Dimensions 
 Easy to Use 
o Easy to Maintain 
o Easy to Monitor 
o Easy to Assemble 
 Easy Cell Sheet Removal 
o Handling  
o Packaging  
o Removal from Bioreactor  
 High Throughput  
o Separate Chambers  
o Generates Multiple Sheets  
12 
 
3.2.1 Automated Nutrient Delivery 
Automated nutrient delivery was an objective for this project because the cells require constant 
nutrients to survive.   Additionally, automation could increase reliability and reproducibility of results.    
3.2.2 Reproducibility 
Reproducibility was a critical objective for this project.   If the design yields a device that can 
generate a sheet, but the sheets are not consistent then the bioreactor has not fulfilled its purpose.   
These sheets could not be used for further research as there would be lot to lot variability.   The sheets 
must be consistently reproducible in terms of mechanical properties and dimensions.   Mechanical 
properties must be uniform in every experiment as to not pose an undue risk of failure after 
implantation.    
3.2.3 Easy to Use 
The next major objective focuses on ease of use.   If the device is too difficult to actually use in a 
laboratory setting, it will not be used and will have failed in its purpose.   The device must be 
maintainable as it is designed for long-term use.   If it fails and cannot be fixed easily, then research will 
be unduly slowed down or it will be forced to move in another direction.   Failure also introduces 
financial concerns; the cost of manufacturing becomes superfluous if the machine does not work, 
replacing parts can become very pricey, and loss of materials can also add up quickly.    
The bioreactor should also allow monitoring of the cell sheet during cell culture.   It will allow 
users the ability to check on the progress of sheet growth and notice any unusual developments that 
would affect the final product.    
The bioreactor should also be easy to assemble.   More difficult assembly may be acceptable 
under the condition that assembly is only required to occur once.   If repeated assembly is required, 
then it must be user-friendly.   Should the user deem that setting up the device is more difficult than its 
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potential benefits, they will find alternate means of creating the cell sheet, and this device will not be 
used.    
3.2.4 Easy Cell Sheet Removal 
Another major objective is easy cell sheet removal.   After removal the sheet must be sturdy 
enough to handle as it will either undergo further testing or implantation.   A sheet that is too delicate 
for future manipulation is not useful to the user or client.   Also, the cell sheet must be removed from 
the device intact for both research testing and future implantation.   If the sheet is compromised during 
the removal process, then any time and effort spent culturing the sheet was wasted.    
3.2.5 High Throughput 
Throughput is the ability to produce sheets rapidly or in large numbers.   To increase 
productivity of the bioreactor, it should output more than one cell sheet per culture period.   This will 
decrease variability between batches for research purposes as there will be more sheets cultured under 
the same conditions.   This method will also decrease time needed for experimentation as users will not 
have to wait separate cell culture periods for multiple sheets.   All cell sheets must be consistent in 
terms of mechanical properties and dimensions.   Ideally, multiple sheets will be cultured in separate 
chambers with an independent nutrient delivery system to all chambers.   This would prevent one faulty 
chamber from ruining every sheet being cultured that cycle.    
3.3 Weighted Objectives 
Following the development of primary and secondary objectives, the team had to ascertain the 
importance or weight of each primary and secondary objective.   To accomplish this, the team created 
an objective tree that showed the relationship between the primary and secondary objectives.   To 
establish the importance of each objective, the team met with the client, Dr. Marsha Rolle, and pairwise 
comparison charts were generated for all primary and secondary objectives which can be seen in 
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Appendix A.  The results of the pairwise comparison charts were analyzed, and the objectives were 
weighted accordingly.   The objectives and their weights can be seen in the objective tree in Figure 2.    
 
Figure 2: Weighted Objective Tree 
 The weighted objectives showed the importance of each objective in regards to the other 
objectives.   The weights showed that the objectives should be addressed in the following order: 
 Reproducible 
 Throughput (>1 sheet) 
Create a Bioreactor that 
Generates a Tissue Patch
(1.0)
Automated Nutrient 
Exchange
(.35)
Throughput
(.30)
Template Material No 
Longer Present
(.44)
Layers Have 
Attached/Aligned
(.33)
Generates Multiple 
Patches
(.22)
Separate Chambers 
(.11)
Easy Patch Removal
(.20)
Removal from Bioreactor 
(.42)
Handling
(.42)
Packaging
(.17)
Reproducible
(.10)
Mechanical Properties
(.67)
Sheet Dimensions
(.33)
Easy to Use
(.05)
Easy to Monitor
(.67)
Easy to Assemble
(.17)
Easy to Maintain
(.17)
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 Easy Cell Sheet Removal 
 Easy to Use 
 Automated Nutrient Delivery 
3.4 Functions 
After analyzing the design objectives, a list of functions was established.   As this project is 
comprised of two major components (the bioreactor and the cell sheet output), a list of functions 
specific to each were developed.   The following lists show the functions the bioreactor must accomplish 
and the functions the cell sheet must realize in order to achieve the established objectives. 
Bioreactor 
 Generate a cell sheet 
 Seed cells 
 Feed cells 
 Easily release sheet 
 Allow user monitoring  
Cell Sheet 
 Produce matrix 
 Exhibit enough strength to hold tissue together 
 Interface with host body tissue similarly to natural cells 
The overall goal of the project was to create a bioreactor that outputs a mechanically strong, 
thick cell sheet.   There are not currently bioreactors that easily output, in one step, cell sheets greater 
than a few cell layers thick.   To accomplish this goal, the bioreactor must be able to perform the 
established functions.   If the bioreactor does not output a cell sheet, then achieving the projects goal is 
impossible and the design will have failed.   A critical function is delivering the cells into the device and 
retaining them in the chamber.   Cells are living and if they are not fed, then they die.   Therefore the 
bioreactor must be able to deliver nutrients.   The bioreactor also must not leak or there will be 
problems with both sterilization and nutrient delivery.   The bioreactor must also assemble the cells into 
tissue or the output will not be a cell sheet.   The sheet must be able to be removed from the bioreactor 
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so the bioreactor’s cell culture chamber must come apart to facilitate cell sheet removal.   Also, it must 
allow monitoring by the user to optimize culture periods and evaluate cell growth over the cell culture 
cycle. 
The sheet must possess appropriate histological organization to achieve adequate tissue 
integrity. Both cellular alignment and ECM production are necessary to achieve adequate structural 
stability.  If the cell alignment is abnormal then this can lead to functional defects in the tissue. (Grenier, 
2005) Also, lacking structural stability will lead to mechanical failure.   If the tissue fails mechanical 
testing, it will not have enough strength to hold tissue together and will not be able to be applied as a 
cardiac patch.   The cell sheet must also interface with host body tissue similarly to natural cells, to 
prevent cell death, additional damage to native tissue, or rejection of the patch.    
3.5 Constraints 
 In order to reduce the design space for this project and ensure that the client’s needs were met, 
constraints were established.   The constraints were as follows: 
Constraints 
 Size 
o The bioreactor must be able to fit inside an incubator 
 Sheet Size 
o The sheet size must be appropriate to developed testing devices 
 Cell-derived 
o The sheet must be cell-derived and the final product contain only cells and cell-derived 
extracellular matrix 
 Implantable 
o The sheet must be implantable and therefore biocompatible 
 Sterilize-able 
o The bioreactor must be able to be sterilized  
 Time 
o The project must be completed by April 2009 
 Budget 
o The project cannot cost more than the allotted project budget of $624 
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The constraints were consulted when evaluating alternative designs.   If a design violated an 
established constraint, it was then rejected as undesirable.   The bioreactor must be able to fit inside an 
incubator since cell culture requires specific environmental controls and the best way to maintain this is 
an incubator.   The cell sheets will be tested by a mechanical testing device that has already been 
developed. (Ahlfors, 2007) In order to use this device, the sheet must be of an appropriate size.   Unlike 
other current products, this sheet must be completely cell-derived.   This will eliminate unwanted 
complications with scaffolds, and allow the research of solely cells rather than scaffolds and cells.   The 
goal of this project was to produce a cardiac patch; therefore the sheet must be sterile, biocompatible 
and appropriate for implantation.   Finally the design must be within budget and completed by April 
2009. 
3.6 Specifications 
 Establishing specifications was an important step in the design process.   Specifications help 
focus the design process, by assigning numerical values to assist in the realization of objectives.   The 
specifications for the bioreactor design can be found in Table 2.   The cell sheet must be at least 15mm 
in diameter.   This size is the minimum diameter that is necessary for mechanical testing protocols.  The 
bioreactor must fit in an incubator with 3 inch shelves.   This bioreactor will be used in labs with this size 
limitation, and for the bioreactor to be useful it must meet this specification.   
Table 2 - Specifications 
Specification Description 
Output a Cell Sheet Greater than 15 mm in diameter 
Bioreactor Size Must fit in an incubator, 3inch shelf size 
Sample Size Must generate greater than 5 samples per trial 
 
18 
 
The cell sheet must be at least 15mm in diameter.   This size is the minimum diameter that is 
necessary for mechanical testing protocols.  The bioreactor must fit in a standard incubator – a fairly 
standard shelf height is 3 inches.   This bioreactor will be used in labs with this size limitation, and for the 
bioreactor to be useful it must meet this specification.  Additionally, to achieve high throughput, each 
run of the bioreactor must produce at least 5 samples per trial.   
3.7 Revised Client Statement 
The objectives of this design are to design a bioreactor that is: 
 Reproducible 
 Allows easy cell sheet removal 
 High Throughput 
 Easy to use 
 Automated (nutrient delivery) 
The functions of this design are to: 
 Generate a cell sheet 
 Accept/support cells 
 Feed cells 
 Assemble cells tissue into a sheet 
 Easily release sheet 
o Chamber must come apart 
o Chamber must not leak 
The constraints of this design are: 
 The bioreactor must be able to fit inside an incubator 
 The sheet size must be appropriate to developed testing devices 
 The sheet must be cell-derived and the final product contain only cells and cell-derived matrix 
 The sheet must be implantable and therefore biocompatible 
 The bioreactor must be able to be sterilized  
 The project must be completed by April 2009 
 The project cannot cost more than the allotted project budget of $624 
The specifications of this design are: 
 Output a cell sheet in the following dimensions: Diameter greater than 15 mm 
 Fit in incubator: shelf height 3 in 
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 Sample size: greater than 5 samples/trial 
4 Design Alternatives 
 After determining the client’s needs and wants, and effectively determining the objectives, 
specifications, functions, and constraints of the project, it was necessary to begin developing alternate 
designs.   The first step was to determine the means to achieve the specified functions.   These means 
allowed focus of potential materials and methods into different conceptual designs, which were 
evaluated for feasibility and optimization.    
4.1 Means 
 Once the functions were determined, it was necessary to determine the means to accomplish 
them.   The functions were determined to be that the bioreactor generates a cell sheet, by seeding the 
cells, feeding the cells, easily releasing the final tissue sheet and allowing for user monitoring.   A 
functions-means table, to list and compare the potential solution elements for each requirement, was 
created.   The results from this can be seen in Table 3.    
Table 3 - Function-Means 
Functions Means 
Seed Cells Perfusion Rotation Centrifugation Degradable 
Surface 
Coating 
Static/ 
Perfusion 
Centrifugation
/Perfusion 
Column Static 
Feed Cells Perfusion Static 
Feeding 
Osmosis Column Gravity    
Generate a 
Cell Sheet 
Surface 
Modification 
Patterning 
Limit 
Space 
Non-adhesive 
material 
     
Easily Release 
Sheet 
Temperature 
Sensitive 
Surface 
Coatings 
Surface 
Modification 
Non-adhesive 
Material 
Modular    
 
Some of the means defined in the Function-Means Table were immediately dismissed, due to 
constraints, such as time, expertise, materials, etc.  For example, centrifugation and rotation, when 
considered in light of the constraint that the bioreactor must fit within an incubator, were determined 
to present more of a challenge than some of the other options.  It was determined that creating a 
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bioreactor that could accomplish those means within the constraints would take unnecessary time.  
Similarly, the temperature sensitive material, upon further inquiry, appeared to be more difficult than 
helpful in the grand scheme of the project. 
Additionally, certain means were common to multiple functions and it was determined that 
certain means for each function were not exclusive, and had the potential to be combined to better 
solve the problem.  Greater weight was given to those means that would more efficiently accomplish 
the objectives.  The common means are highlighted in Table 4.  
Table 4 - Common Means 
Functions Means 
Seed Cells Perfusion Rotation Centrifugation Degradable 
Surface 
Coating 
Static/ 
Perfusion 
Centrifugation
/Perfusion 
Column Static 
Feed Cells Perfusion Static 
Feeding 
Osmosis Column Gravity    
Generate a 
Cell Sheet 
Surface 
Modification 
Patterning 
Limit 
Space 
Non-adhesive 
material 
     
Easily Release 
Sheet 
Temperature 
Sensitive 
Surface 
Coatings 
Surface 
Modification 
Non-adhesive 
Material 
Modular    
Once the means had been filtered down to the most possible and most efficient, the remaining 
means were re-considered, compared and weighed, until only the best, most feasible options remained.  
The means decided upon to satisfy the functions are described in Table 5.  
Table 5 - Selected Means 
Function Means 
Seed Cells Degradable Surface Coating, Perfusion 
Feed Cells Perfusion, Column 
Generate Cell Sheet Limit Space, Surface Modification, Non-adhesive Material 
Easily Release Sheet Surface Coating, Surface Modification, Non-adhesive 
Material 
 
 The final means being investigated were combinations of common means between functions 
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and combinations of means within functions that seemed to offer the best options.  For the bioreactor 
to allow the seeding cells into it, a degradable surface coating, such as fibrin gel, would be used 
concurrently with perfusion.  Perfusion would also allow the bioreactor to efficiently deliver media to 
the cells to accomplish feeding them.  A column-like shape would also help make this process more 
effective, by gathering the cells in one location and taking advantage of gravity to assist with media 
perfusion.  This shape would limit space, assisting with the generation of a cell sheet; by restricting the 
surface area that the cells can spread out across, density of the cells per unit area is higher.  This allows 
for more cell-to-cell contact, which increases attachment, and generates a thicker sheet.  To further 
allow the bioreactor to generate a cell sheet, surface modification and a non-adhesive material were 
used, to help encourage the cells to attach to each other instead of the culture material surface.  These 
qualities of that surface, as well as some sort of coating, would also permit easy release of the sheet, 
with minimal damage, as the cells will have primarily adhered to each other and only minimally to the 
surface material.   
4.2 Conceptual Designs 
Once the means were narrowed down, conceptual designs were developed to determine 
feasibility and materials.  With so many potential means to realize the necessary design functions, 
multiple designs were considered.   Each of the alternative designs was developed by examining various 
combinations of the described solution elements.    
 Initially, it was necessary to find materials for the cells to be seeded onto that would encourage 
attachment as well as permit easy release.  As defined previously, these materials would need to be 
non-toxic, sterilizable, and easily release the sheets after culture.  Preferably, these materials should 
also be easy to obtain, commonly used, and fairly inexpensive. 
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 The next step was to design housing for the culture materials.  The initial design was a simple 
horizontal perfusion box, involving horizontal flow of media across the culture materials.  A diagram of 
this design alternative can be seen in Figure 3. 
 
 
Figure 3: Conceptual Design - Box 
 
The next alternative was a column shape.  This was designed for a number of reasons.  To begin 
with, the column was determined to be a means that would assist in generating a sheet, while at the 
same time providing a means to feed the cells – utilizing gravity.  Additionally, many common culture 
materials have a round shape, for example, both the Transwells and NPRs mentioned earlier are round.  
This alternative can be seen in Figure 4.   
 
Figure 4: Conceptual Design - Column 
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This conceptual design was developed further after referencing the design objectives, 
specifically automated nutrient exchange and high throughput.  Housing with multiple chambers was 
designed, allowing for a greater number of samples per trial.  Additionally, a media distributor was 
incorporated, to assist with nutrient delivery.  This conceptual design can be seen in Figure 5.   
 
Figure 5: Conceptual Design – Complex 
4.3 Materials 
 In order to move from a conceptual design to an actual design – to move from the theoretical to 
the physical – it was necessary to determine what materials to use.  Given the multiple components of 
the bioreactor, even in the conceptual stage, the list of potential materials was fairly long.  To organize 
the possibilities, the materials for each component were arranged below, in Table 6.  The materials for 
each component are discussed in the following sections. 
Table 6 - Possible Materials for Components of the Design 
Component 
Body of Bioreactor PC PP PMMA Stainless 
Steel 
Glass  
Chamber for media & cells PC PP PMMA Alumina  Stainless  
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Steel 
Coating to Prevent Cell 
Adhesion 
FEP 
membranes 
Sigmacote PIPAAm  Cellulose 
esters 
PTFE Nitex 
Degradable Coating Fibrin Collagen Hyaluronic 
acid 
Agarose   
Tubing Silicon       
Media DMEM – 10% 
Bovine 
Serum & Pen 
Strep 
DMEM 
+Ascorbic 
acid 
    
* Acronyms in the above table are as follows: PC (polycarbonate), PP (polymethylmethacrylate), FEP (fluorinated 
ethylene-propylene) PIPAAm (poly (N-isopropylacrylamide)), and PTFE (polytetrafluoroethylene) 
4.3.1 Body of Bioreactor 
 It was decided that the bioreactor housing was to be manufactured out of polycarbonate and 
acrylic.  These materials were chosen because they can be autoclaved (sterilized), are durable, clear 
(allowing user monitoring), and reasonably available and priced.   (Dynalab Corp.)  It was also decided 
that a flow distributor for media delivery would be manufactured out of a polycarbonate sheet, with 
multiple holes to distribute the media evenly throughout the bioreactor.   Stainless steel screws will be 
used to attach the cover to the base, because they are strong and sterilizable, as well as easily obtained 
and fairly inexpensive.   
4.3.2 Chamber for Media & Cells 
 The chamber for media and cells was incorporated into the bottom of the chamber to create a 
media reservoir.  This removed any need for an external media source, instead storing it in the bottom 
of the base itself.  This, as stated above, was to be machined of acrylic and polycarbonate.  
4.3.3 Culture Materials 
Various coatings and materials which would allow easy cell sheet release were investigated.   
Fluorinated ethylene propylene has been used in previous studies to prevent cells from adhering to the 
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surface.  Covering the surface with a temperature-sensitive polymer would also allow easy sheet 
removal and has also been considered.   (Matsuda, 2007)  (Shimizu, 2002)  These were dismissed 
because their porosity was too low to allow the necessary diffusion of media.  
Transwells are plastic cylinders with a permeable membrane at the bottom. The cells are seeded 
and cultured on the membrane. Mainly Transwells made of PTFE and mixed cellulose esters have been 
used for more effective cell growth and easy cell sheet removal.  Two Transwells considered were a 
Biopore™ (PTFE) and a MF-Millipore™ (mixed cellulose esters).   Each of these options has unique 
characteristics that better recognize different objectives. 
Biopore™ (PTFE)  
Teflon (PTFE) membranes, specifically, the hydrophilic PTFE with 0.45 micrometer pore size is 
commercially available under the name BioporeTM from Millipore. 
 
Figure 6: Biopore™ (PTFE) membrane 
 
It has been selected for its low protein binding properties which are very useful for cell growth.  
Protein binding is essential for cell attachment; therefore a surface with low protein binding will allow 
the cells to adhere, but not in an irremovable manner.  The rounded dermal fibroblasts have a diameter 
of 20 μm.  This pore size should permit the diffusion of media and should retain the cells inside the 
chamber but this will have to be further investigated experimentally.   (Harley, 2007)   
MF-Millipore™ (mixed cellulose esters)  
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MF-Millipore TM membrane filter is composed of biologically inert mixtures of cellulose acetate 
and cellulose nitrate.  The material was selected for its non-adhesive properties which should allow easy 
sheet removal.  The same pore size as for PTFE membrane (0.45µm) was selected based on cell size.  
However, the pore structure of the Millipore membrane is different from PTFE and the material should 
be more permeable and allow easier media perfusion.   
 
 
Figure 7: MF - Millipore Membrane 
 
There are a number of potential challenges with using these membrane filters.  First, the pore 
size (0.45 um) might be too small to allow sufficient media outflow.  Second, the pores in the membrane 
could potentially become constricted or clogged by the cells, which would completely disable media 
outflow. 
Nitex/Polyethylene Constructs 
Nitex mesh was also examined as an alternative material.  Nitex is a nylon mesh that does not 
degrade and is autoclavable. It is widely accepted as a material compatible with tissue culture.  The pore 
size (50-350 µm) was large enough to eliminate any potential clogging, however the high porosity could 
impose some difficulties with cell seeding.  To make the Nitex mesh more manageable and help with 
sheet development, porous polyethylene rings were adhered to either side of circular pieces of Nitex 
mesh, creating a better culture surface for the cells.  Additionally, the porous rings would act as anchors, 
encouraging the cells to grow into them.  This would help reduce contraction when the sample was to 
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be harvested.  A diagram of these Nitex/polyethylene constructs can be seen below, and will be referred 
to as NPRs from this point forward. 
 
Figure 8: Diagram of NPRs 
4.3.4 Degradable Coating 
     To assist with seeding the cells, generating a cell sheet and also easily releasing that sheet, a 
degradable coating was considered.  The basic idea was that a material would be present at culture that 
would promote cell aggregation and proliferation from the time of seeding. However, this material 
would have to be gone by the time the sheet was harvested, to ensure that the result was completely 
cell-derived.  So, the concept of a ‘sacrificial template’ was investigated – a material that would be 
present at the beginning of culture to help encourage the cells to attach, but would degrade over time, 
and be completely gone by the time the sheet was release.  A fibrin or a collagen gel could serve as such 
a sacrificial template, under the condition that complete dissolution of the gel would occur by the time 
the tissue construct was formed. 
Nontoxic biodegradable natural materials such as collagen, fibrin and hyaluronic acid have been 
explored as possible scaffold materials because they do not trigger foreign body response upon 
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implantation and integrate well with the surrounding tissue. (Zhaodi, 2006)  These materials alone are 
not sufficient to serve as a cardiac patch. It is important to note that fibrin increases the synthesis of 
both collagen and elastin when seeded with cells.  (Zhaodi, 2006) Increased production of collagen and 
elastin yields tissue constructs with improved mechanical properties.    Specifically, compliance is 
determined by the elastin content of the scaffold.  Compliance match between the scaffold and the 
heart tissue is crucial to maintain the functionality of the heart during contraction. While fibrin is not an 
acceptable material for the basis of a cardiac patch due to its weak mechanical properties, it could be 
used as an aid in the culture process.  (Ahlfors, 2007)   A fibrin gel could be used as a sacrificial template 
that allows the cells to form a sheet with it initially, but would be digested by the time the sheet was 
ready to harvest. This would take advantage of the positive properties of fibrin and help resolve the 
issue of the high porosity of Nitex, while still ensuring that the end product was a totally cell-derived 
tissue patch.  
4.3.5 Tubing 
Silicon tubing will be used to perfuse the media and connect the components.   Silicon tubing 
allows for gas exchange within between the closed system and the incubator environment.   A peristaltic 
pump will be used to pump the media through the bioreactor.    
4.3.6 Media 
Regular media DMEM – 10% Bovine Serum & Pen Strep will be used, as instructed by our 
advisor.   Addition of ascorbic acid has been considered to promote cell proliferation and collagen cross-
linking.  Adding ascorbic acid to the media will produce a mechanically stronger cell sheet.  (Grenier, 
2005)    
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4.4 Design Matrix 
A separate list of objectives was established for the culture materials.  Each of the identified 
objectives was ranked as equally important; the chamber must: allow for easy sheet removal, allow 
media perfusion, and retain cells.   A separate design rubric was established for the three different 
alternative materials for the permeable chamber component.   The materials were evaluated for 
realization of bioreactor chamber objectives, and these results can be seen in Table 7 and Table 8.   The 
three different membrane filter materials being considered – the two different Transwells and the NPRs 
- were scored with respect to the objectives using the following grading system: 
Score: 
1- Extremely Difficult  
2- Difficult  
3- Moderately Difficult  
4- Fairly easy  
5- Extremely simple 
 
 
Table 7 - Evaluation of Materials for Realization of Bioreactor Chamber Objectives 
Objective/Score 1 2 3 4 5 
Easy sheet Removal  
Biopore(PTFE), MF-
Millipore Nitex+Fibrin   
Allows media 
Perfusion 
  Biopore (PTFE) MF-Millipore  Nitex+Fibrin 
Retains cells 
   
Nitex+Fibrin 
 
MF-Millipore, Biopore 
(PTFE) 
 
Table 8 - Weighted Evaluation of Materials 
  Biopore Millipore Nitex+Fibrin 
Objectives 
Weight   
% 
Score 
Weight 
score 
Score 
Weight 
score 
Score 
Weight 
score 
Easy sheet Removal 33.33% 0.4 13.32% 0.4 13.32% 0.6 19.99% 
Allows media 
Perfusion 
33.33% 0.4 13.32% 0.6 19.99% 1 33.33% 
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Retains cells 33.33% 0.6 19.99% 1 33.33% 1 33.33% 
Total 100%  46.63%  66.64%  86.65% 
 
Although it was determined that the NPRs with a fibrin gel would best accomplish our 
objectives, this construct requires multiple materials, closing a gap in knowledge/experience (developing 
the fibrin gel), and assembly.  For all these reasons, it was decided that the preliminary design would 
focus on the use of the commercially available and commonly used Transwells.  This would also allow for 
more accurate comparison of results to published research. 
4.5 Preliminary Design  
Once the objectives, specifications, functions, and constraints were all determined from the 
client’s design criteria, different means and materials were weighed, leading to alternatives, which were 
then compared and modified, resulting in the preliminary design.  This selected design had multiple 
components – a large, hollow base that incorporated the media reservoir (Figure 9) an insert to support 
culture materials (Figure 10) and a media delivery system (Figure 11).  The insert allowed for multiple 
Transwells to be suspended over the media well, while a perfusion pump would circulate media (and 
potentially additional cells), distributed by a trough-like irrigation system to each of the Transwells.   The 
bioreactor has small enough dimensions to fit inside an incubator, while maximizing on that space to 
allow for sufficient media.   A picture of this device can be seen below in Figure 12.    
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Figure 9: Preliminary Design - Media Reservoir 
 
 
Figure 10: Preliminary Design - Culture Material Support Insert 
    
 
Figure 11: Preliminary Design - Irrigation Trough Lid 
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Figure 12: Photo of Preliminary Design 
 
As mentioned, there are multiple components to this design.   Each part plays a crucial role in 
helping to achieve the specifications.   The base has a reservoir for media, to ensure cell life and health, 
and help retain natural mechanical properties.   The insert allows for separate chambers that enclose 
each sheet, encouraging the cells to grow together into individual sheets.   The media distributor 
ensures that equal amounts of media are delivered to each Transwell, and decreases the forces the 
falling media enacts on the cells and sheets.   All of these components have been designed to optimize 
the health and strength of the cell sheets, while staying inside the size requirements.   The media well of 
the bioreactor is a machined block of acrylic, with the egg-crate insert and irrigation system/lid are 
machined polycarbonate.   Stainless steel fittings and silicone tubing is used to circulate the media.   CAD 
renderings of the device can be seen below in Figure 13.  
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Figure 13: Schematic of Final Design 
 
5 Design Verification 
A number of tests were conducted on the final design.   These tests were run to determine how 
well the designed bioreactor system achieves the set objectives and functions to the specifications 
within the constraints.   The tests included fluid flow and functionality testing.    
5.1 Fluid Flow Testing 
 The bioreactor system was run to determine the best flow rate for the system that would deliver 
sufficient media to all of the cells, while minimizing the forces exerted on the developing tissue sheets.  
To ensure media was being equally distributed to each sample, flow rate was measure through each 
distribution port.  To test this, media flow was measured through each distribution port for 1 minute 
periods.  The Masterflex peristaltic pump (Model No: 7518-10) was set at a rate of 3.5ml/min for all 
trials.   The media was collected from each distribution port specifically and the volume recorded (in 
milliliters) was used to calculate the flow rate per port.  The results from the initial testing can be seen in 
Figure 14.  As seen in Figure 14, the results were inconsistent in more than one way.  There was high 
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variability between the flow rates across all the ports.  There was also high variability within many of the 
ports, showing inconsistencies over time (trial to trial).   The average flow rate delivered to each well 
was 3.5 ± 2.7 mL/min.   
 
Figure 14: Design 1 Flow Testing 
5.2 Performance Testing 
 The bioreactor system was tested to ensure that it could be run successfully.  The preliminary 
design was run outside the incubator for 2 days, simply to determine if it could be run effectively while 
the peristaltic pump was constantly re-circulating media.  Effectiveness was determined based on 
whether the bioreactor ran without leaking or any sort of overflow of media.  After this time period, 
there was no evidence of leakage or flow problems.  This test was deemed a success.  It was then tested 
whether or not the bioreactor could be sterilized, that is, withstand the high temperatures of an 
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autoclave.  Unfortunately, the acrylic base deformed in the autoclave, enough that it was no longer a 
useful component.  
5.3 Preliminary Design Conclusions 
 As the acrylic base deformed in the autoclave, it was determined that re-machining the 
bioreactor out of a different material was necessary.  As the polycarbonate components had the desired 
properties regarding strength and sterilizability, and also retained their shape after being autoclaved, 
the new base was to be machined out of that material.  As the initial design was successful as far as flow 
through the system without leaking, the general design of the system could remain the same.  However, 
as the flow testing failed quite badly, it was determined that this component would need adjustments.  
Upon further inspection, potential reasons for the poor results were discovered.  The most obvious 
drawback of this design was the lack of control afforded the user; there was no mechanism to assist the 
user in delivering specific amounts of media to the different ports or in priming the system.  
Additionally, the holes in the ports had been machined using a handheld drill, increasing error in the 
sizes of the holes and the angles at which they were drilled.  While the option of modifying the 
preliminary media delivery system was available, it was decided that a greater amount of control was 
desired, and therefore a redesign of this component was necessary.   
6 Final Design and Validation 
 
 The team was charged with developing a bioreactor system to rapidly and reproducibly fabricate 
and culture mechanically stable cell-derived tissue sheets.   The objectives of this design were 
determined to be that the bioreactor system easily and consistently generate multiple, healthy cell 
sheets that have comparable mechanical properties and are easily removed from the system.   
Consideration of these objectives led to the establishment of a functions list.   These functions were 
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ascertained to be that the bioreactor must generate a cell sheet, accept and support cells, feed said 
cells, assemble those cells into tissue, and then easily release that sheet.   The realization of these 
functions was constrained by the size of the bioreactor, the size of the resulting sheet, the composition 
of the final sheet – completely cell-derived and devoid of any synthetic materials, implantability, 
biocompatibility, sterilizability, time – completed by April 2009, and money – within a budget of $624.   
The specifications of the design were that the bioreactor system must output a cell sheet with a 
diameter greater than 15 mm, which will fit in incubator with a shelf height of 3 inches.    
6.1 Final Design 
After analyzing the results of the validation tests of the preliminary design, it was determined 
that many of the results were unacceptable.  It was necessary to reexamine how the final design was 
going to satisfy the objectives and functions.  A detail Bill of Materials for the final design can be found 
in Appendix D.  
6.1.1 Final Design of Media Reservoir 
 Given that the reservoir from the preliminary design deformed during the autoclave process, a 
new base was fashioned.  It was determined that the new base would be machined out of 
polycarbonate, for strength, sterilizability and translucence.  The base has a lip inside to support the 
culture material inserts, and an upper lip to support the media distribution system.  The reservoir holds 
approximately 500 mL of media – enough to sustain cell health for a prolonged culture period without 
manual media exchange. 
6.1.2 Final Design of Media Distribution System 
As concluded from the results of testing the preliminary design, the media distribution system 
needed to be redesigned, as it was failing to consistently deliver sufficient media through each port.  To 
resolve these problems, increase user control, and improve the overall functionality of the media 
distributor, it was redesigned utilizing stainless steel set screws from McMaster.  This design feature 
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allows the flow rates from each hole to be controlled independently.  A schematic diagram explaining 
this can be seen in Figure 15.  
 
Figure 15: Set Screw Schematic 
The set screws can be fine-tuned for each port, to allow the media distributed to each sample to 
be adjusted to a specific rate.  A picture of the new media delivery system can be seen in Figure 16.   
 
Figure 16: Final Design - Media Distribution System with Set Screws 
 
6.1.3 Final Design of Culture Material Supports 
The redesign of the media distributor opened up additional options for cell culture.  For 
example, now that specific ports could be closed, static culture and dynamic culture could now be run 
concurrently.  This redesign also led to a redesign of the culture material supports; different inserts were 
machined.  Four inserts were machined, each about the size of a six-well plate.  Two of the inserts were 
created to support six 6-well sized Transwells, and two inserts were created to hold six NPRs.  A photo of 
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one of each insert can be seen in Figure 17.  These inserts were designed with the option of using any 
combination of the different types; each culture can be run with a choice between twelve Transwell 
samples, twelve NPR samples, or six of each.   
 
Figure 17: Final Design - Inserts 
6.2 Final Design Assembly 
As in the preliminary design, the inserts and the media delivery lid all sit inside of the base that 
contains the media reservoir.  Again, the silicone tubing re-circulates the media, using a peristaltic 
pump, from the media well up through the irrigation system.  A photo of the entire system can be seen 
in Figure 18.  
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Figure 18: Final Design 
 To begin with, the media is poured into the base (Figure 19) before the inserts are set inside 
(Figure 20).  The culture materials are then placed in their respective inserts (Figure 21).  The media 
distributor is then placed on top of the bioreactor, and each individual port is fine-tune adjusted for 
whatever flow rate is desired for that sample (Figure 22).  Finally, the bioreactor is placed in the 
incubator (Figure 23).   
 
 
Figure 19: Assembly - Reservoir 
 
 
Figure 20: Assembly - Inserts 
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Figure 21: Assembly - Culture Materials 
 
Figure 22: Assembly - Media Distributor 
 
Figure 23: Assembly - Incubator 
6.3 Testing  
The final design of the bioreactor system was again tested to determine how well it achieves the 
set objectives and functions to the specifications within the constraints.  The tests again included fluid 
flow and functionality testing to validate the newly designed components.    
6.3.1 Fluid Flow Testing 
  The final design of the bioreactor was again run to determine the best flow rate for the system 
that would deliver sufficient media consistently through all the ports.  Flow testing was repeated with 
the new design, to determine its feasibility, and, ultimately, its superiority to the preliminary design.  
Again, media flow was measured through each distribution port for 1 minute periods.  The peristaltic 
pump was set at a uniform rate for all trials.   The media was collected from each distribution port 
specifically and the volume recorded (in milliliters) was used to calculate the flow rate per port.  The 
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results from the initial testing can be seen in Figure 24.  As seen in the graph, the results even from the 
first trial were more consistent between ports than was observed with the previous design.  The set 
screws were adjusted between each trial, in an attempt to determine whether the flow could be fine-
tuned and controlled through each port.  By the third trial, the average flow rate was 8.5 ± 0.7 mL/min, 
and the flow rate for the final trial was 9.1 ± .1 mL/min.  This test – to determine if the flow could be 
controlled as well as consistent – was determined to be a success.  
 
Figure 24: Fluid Flow Testing of Final Design 
6.3.2 Performance Testing 
The redesigned bioreactor system was tested to ensure that it accomplished all the design goals 
– meeting objectives, performing functions, etc.  To begin with, the system was autoclaved to sterilize all 
the components.  This was completed without any deformations or negative effects to the apparatus.  
The bioreactor was then tested to determine if it could be run successfully in the incubator.  Testing 
success was determined by whether or not the bioreactor leaked or backed up, and if the media 
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remained clear and free from contamination throughout the testing period.  The bioreactor was run 
inside the incubator with only media for 4 days.  After this time period, there was no evidence of 
leakage or flow problems, and the media remained clear.  This test was also deemed a success.   
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7 Discussion 
 This design solved the problem stated in the background, achieving the described objectives and 
functions. This will allow a user to cultivate up to twelve tissue sheet samples per trial without user 
intervention for multi-week periods. The controllable flow rate to each port will allow testing multiple 
materials in one trial. This design has wide-reaching implications as it expands research possibilities. 
7.1 Significance 
 Simplified, the problem is that no device exists that can facilitate the generation of purely cell-
derived patches to be used to treat different heart problems.  Such a device was created that is easy to 
use, capable of automated nutrient delivery, produces multiple samples per trial, allows for easy 
removal of the resulting patches, which have comparable properties.  These objectives are accomplished 
by the bioreactor allowing for seeding of cells into it, delivering media to feed the cells, encouraging the 
cells to aggregate in order to generate a patch, and then easily release that patch.   
 The different components of the bioreactor have many advantages, in addition to promoting the 
generation of these wholly cell-derived patches.  The media reservoir base eliminates the need for an 
additional, external media source.  The inserts allow for the use of multiple different culture materials – 
concurrently, if desired.  The media delivery system is fine-tunable for each individual sample, allowing 
for adjustments for different cell types, culture materials, and culture methods.  When fully assembled 
and connected to the peristaltic pump, the entire bioreactor fits within an incubator, on a 3 inch high 
shelf.   
 There are limitations to this design.  While the bioreactor does allow for the use of common 
culture materials that have been proven to promote cell aggregation, and can consistently maintain the 
proper conditions for cell culture, testing of cells in the system has not occurred.  Also, while the culture 
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materials were chosen for their material properties with the intent that they would limit cell adhesion to 
those surfaces and promote aggregation and attachment within the generated sheet while additionally 
allowing easy sheet removal, cell culture was not completed, leaving this unconfirmed.  These aspects of 
the design have not yet been validated.  There are additional modifications that should be made to 
optimize this design.  For example, 500 mL of media could be too high a volume for certain cultures, and 
adjustments to reduce this should be available.  Also, specific flow rates should be determined for 
specific cultures.   
In order to validate additional aspects of the design, a number of tests should be run.  For 
example, extensive contamination testing should be performed.  Once it has been verified that the 
bioreactor possesses the ability to remain sterile, fluid flow tests with different culture materials should 
be run, to determine the best flow rates for the different materials.  Once this has been completed, cells 
should be seeded on the different culture materials and the bioreactor should be run for extended 
periods of time, allowing the cells to aggregate into cell sheets.  Removal of the sheets from the culture 
material should be examined, to determine if the materials properly restrict adhesion while allowing for 
easy removal.  The resultant sheets should then undergo histology and mechanical testing. 
7.2 Implications  
There are a number of factors to be considered when designing a product for mass production.  
There can be a number of implications or consequences, specifically concerning a product in the medical 
sector.   Some of these necessary considerations might be economical, environmental, social, political, 
ethical, or concerning safety, manufacturability or sustainability.  
7.2.1 Economics 
Tissue engineering is a fast evolving field and “more than $3.5 billion has been invested in 
worldwide research and development” in the past decade. (McIntire, 2002) Some of the US companies 
involved in tissue engineering are Synthecon, Lifecell, Interpore, Organogenesis, Cytograft and many 
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have realized that the bioreactor technology is essential for developing a functional cardiovascular 
tissue constructs. (ABT, 2003) Synthecon Inc. and Aastrom Biosciences Inc. have been focusing their 
research on bioreactor development and Synthecon bioreactor has been used as one of the models for 
our project. Unfortunately, the commercially available bioreactors are expensive and the associated 
high costs are an obstacle for advancement of tissue culture regeneration. Our design is cost effective 
and allows fabrication of multiple cell sheets at a time. Our design is based on a commercially available 
bioreactor and fulfills the same functions but it is cheaper and easier to maintain. It allows production of 
multiple cell sheets at a time and leads to reduction of lab costs associated with device maintenance and 
operation.  
7.2.2 Environmental Impact 
The operation of the bioreactor will not have a negative effect on the environment. The tissue-
constructs are made from natural materials and are advantageous over synthetic materials such as 
Dacron and other synthetic scaffolds.  
7.2.3 Societal Influence 
The problem of limited supply of donor tissues could be resolved with the advancement of 
bioreactor technology. Biocompatibility and immunogenicity are the most prevalent issues associated 
with current implant methods.  Our bioreactor allows fabrication of human tissue with patient’s own 
cells which eliminates these problems. Tissue engineered cardiac patches have many advantages over 
the current scaffold methods and lack of donor tissue  
7.2.4 Political Ramifications  
As world’s population ages the demand for improved health care and novel tissue engineered 
solutions is more evident than ever. The U.S. Federal Government funding “has positioned the United 
States as a leader” in the tissue engineering industry (McIntire , 2002)and the companies focusing on 
structural tissue engineering such as skin, bone and cardiac are the fastest growing segment of the 
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market. (Lysaght, 2001)  The US has been the leader in the tissue engineering producing “over seventy 
percent of the global patents are invented in the US,” (McIntire, 2002) however, while several skin grafts 
have been patented and received FDA approval, no such cardiac patch has yet been developed. (ABT, 
2003) A functional bioreactor is needed to develop a viable cardiac patch and our product is a pre-
commercial model which will aid further research and development in the field.  
7.2.5 Ethical Concerns 
The bioreactor and the cell-derived tissue construct will greatly improve the standard of living. 
The cells can be grown up to one billion in a culture flask however to improve formation of a cell-derived 
construct the cells will need to be grown in a bioreactor. If the patch is grown from the patient, then 
there will not be any ethical issues about the distribution of donor material. Currently there are 
extensive lists for heart transplants, and if solutions can be grown instead of harvested from donors 
then the ethical concerns about which patients are more worthy will disappear. 
7.2.6 Health and Safety Issues 
Cardiac surgery often utilizes foreign material for replacing damaged heart tissue but these 
materials are subject to failure and can cause “stenosis, thromboembolization, calcium deposition, and 
infection.”  (Shinoka, 2008) The tissue engineered cardiac patch will offer solutions to these health and 
safety issues. We expect that tissue engineered patches will eliminate infection because the source is 
human cells as opposed to allogenic or xenogenic cells.  Stenosis, thromboembolization, and calcium 
deposition are expected to be greatly reduced compared to the foreign material patches. 
7.2.7 Manufacturability 
The bioreactor device is easy to manufacture but close attention must be given to specifications 
during production. The bioreactor is made of polycarbonate and acrylic body with commercially-
available stainless steel fittings and silicone tubing. The materials are easily-accessible and inexpensive 
and the manufacturing of our bioreactor can be easily reproduced. However, while our bioreactor is 
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cost-effective and easy to manufacture, it is still on the laboratory, pre-commercial scale and a number 
of technological modifications will need to be considered.  
8 Conclusions and Recommendations  
The design of the bioreactor was an iterative process that is still not complete. It has met many 
objectives established early in the project, but there are components that still needs to be validated and 
other components where refinement is possible.  
8.1 Conclusions 
The designed bioreactor functions well and meets the objectives set forth at the onset of the 
project.  The bioreactor fits in an incubator and functions in the incubator without leaking or becoming 
contaminated.  All parts are autoclavable so it is easily sterilizable.  In addition flow to all samples is 
controllable.   
 This bioreactor offers exciting possibilities for future work.  It is designed to allow culture of 
patches with entirely human material which meets the initial goal of the project.  The design is very 
versatile allowing the use of multiple culture materials as well as adjustable flow depending on the 
material used.  The bioreactor also requires minimal effort.  Once the cells are seeded, it can be placed 
in the incubator and left until the patches are ready to be harvested, which greatly decreases the time 
and labor required to operate it. 
8.2 Design Refinement and Validation 
 While the bioreactor functions properly there are a few design refinements that could be made.  
The first is to determine the amount of media required to run the bioreactor for the expected culture 
time and redesign the base to require less media to run.  The second is to incorporate a bleed valve into      
the irrigation system to assist with priming.  In addition to this other inserts could be manufactured to 
adapt to more culture materials as needed.   
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Patches need to be cultured in the bioreactor and validated to determine the cell viability as 
well as the best culture material.  The patches will be validated with mechanical testing and histology.  
Mechanical testing will be performed with the burst pressure method described in Appendix C - Burst 
Test Method. This test determines thickness, failure tension, failure strain and ultimate tensile strength 
(UTS).  Thickness can also be determined from histology as well as cell viability.  Multiple trials need to 
be run in order to determine lot to lot variability.  The design of the bioreactor also allows the use of 
different cell types that can be tested and compared.  Some of the future recommendations can be 
made regarding our design. Using the same material for the body and the top cover will greatly improve 
manufacturability of the bioreactor. This will eliminate the issues associated with autoclaving which we 
encountered during the design testing. We recommend using polycarbonate for the body of the 
bioreactor because it is more transparent and temperature resistant than acrylic.    
 In particular, the future research will need to be performed on the methods for introducing 
multiple tissue layers. A functional cardiac patch would have multiple cell types: “inner layer of 
endothelium, a layer of smooth muscle cells and an outer layer of connective tissue, produced by 
fibroblasts”. (McIntire, 2002) A more sophisticated way of cell culture will significantly improve the 
current design and should be the major factor for other adjustments to the dimensions, the template 
material and the number of wells.   
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Glossary 
agarose – a polysaccharide gel prepared from agar-agar which is produced from sea-weed 
apical (lumen) – apex, top side 
apoptosis – programmed cell death 
ascorbic acid – vitamin c, a water soluble vitamin 
 atherosclerosis – a buildup of plaque (fatty substances, cholesterol, cellular waste products, calcium 
and fibrin) in the inner ling of the artery, thickening and hardening of arteries 
basolateral – the base and one or more sides 
biocompatible – compatible with living systems (cells, tissue, organs), no risk of injury, cytotoxicity or 
rejection by the immune system 
biodegradable – can be decomposed by biological agents such as bacteria 
Biopore – filter material brand name, hydrophilic PTFE, used for: low protein binding, live cell viewing, 
and immunofluorescent applications 
bioreactor - devices that control environmental and operating conditions to aid biological and 
biochemical mechanisms 
bovine pericardium – protective layer surrounding the heart obtained from a bovine 
burst pressure testing – test done in an inflation device that can determine thickness, failure tension, 
failure strain and ultimate tensile strength 
cardiomyopathy – general term for myocardial, or heart, disease 
cardiovascular disease – a disease of the heart or blood vessels 
cell-derived (solely) – consisting only of cells or made from cells or cell material 
centrifugation – a process which uses centrifugal forces to separate or concentrate materials suspended 
in a liquid 
chitosan – derived from chitin, a polysaccharide found in shellfish, used in many pharmaceutical 
applications 
collagen – a fibrous protein found in connective tissue – bone, tendons and skin 
compliance – inverse of elasticity, measure of the tendency of a hollow organ to resist recoil to its 
original dimensions upon removal of force 
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congenital defects – defects present since birth, acquired during fetal development 
ddH2O – double distilled water 
dermal fibroblast – cells derived from the dermis (skin) 
DMEM - Dulbecco's Modification of Eagle's Medium, culture media 
exogenous – originating outside the body 
expanded polytetrafluoroethylene (ePTFE) – microporous polymer, PTFE commercially known as Teflon 
extracellular matrix (ECM) – matrix surrounding outside of cells that provides support, abundant in 
connective tissue 
FEP membranes – membranes of fluorinated ethylene propylene 
fibrin – an insoluble protein produced in response to bleeding, a major component of the blood clot 
fraction collector – collects samples of the same size, usually from a chromatography column 
histology – study of microscopic anatomy of cells by staining a thin slice of the cells 
hyaluronic acid – major component of the extracellular matrix, contributes to cell proliferation and 
migration 
hydrogel – a colloidal gel with water as the dispersed media 
hydrophilic – has a string affinity to water 
in vitro –outside a living organism 
in vivo – within a living organism 
ischemia - restriction in blood supply resulting in damaged tissue 
laminar flow – non-turbulent flow 
live-dead assay – two color fluorescence assay that determines number of live and dead cells 
lyse – to burst or cut a cell structure  
matrigel – liquid gel extracted from mouse tumor cells and is rich in ECM proteins 
MF-Millipore – filter material made of mixed cellulose esters, used for: exceptional anatomical and 
functional polarization 
myocardial infarction – a heart attack, occurs when blood supply to the heart is interrupted 
nitex – nylon mesh with micron size openings 
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parafilm coating – a flexible film used in the lab for sealing vessels 
PC  - polycarbonate, a thermoplastic polymer 
perfusion – the pumping of fluid through an organ or tissue 
perfusion bioreactor – a bioreactor that uses perfusion to seed and/or feed the cells 
peristaltic pump – a pump which compresses a flexible tube between rollers and pushes fluid forward 
PiPAAm - poly (N-isopropyl acrylamide), a thermoresponsive polymer 
PMMA – poly (methyl methacrylate) clear plastic replacement for glass 
polyethylene anchor 
polyethylene terephthalate (PET) – thermoplastic polymer resin, commercially known as Dacron 
PP – polypropylene, a thermoplastic polymer 
prolene sutures – monofilament polypropylene non absorbable suture 
protein binding – proteins attach themselves to surfaces, such as drugs 
pulsatile flow – throbbing or beating flow, as in blood flow in the heart 
sacrificial template – template material used to initially form sheet but will degrade and will not be in 
the final sheet 
SAMs – self assembled monolayers, formed by amphiphilic molecules with a head and a tail that self 
align 
scaffold – temporary framework material 
seeding – the process of introducing the cells to the culture material 
Sigmacote – silicone solution in heptanes that readily forms a covalent, thin film on glass, retards 
clotting, water repellent 
strain – deformation of material caused by an applied stress 
suture retention test – test performed to determine suturability of the sheet 
systolic – of or relating to systole, the contraction of the chambers of the heart 
tensile strength – strength of the material, greatest longitudinal stress without tearing 
throughput – ability to produce sheets rapidly and in large numbers 
Transwell – a membrane insert used for cell cultures, allows for feeding from two sides 
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ventricular aneurysm – localized dilation or protrusion on the wall of the left ventricle occurring after a 
myocardial infarction 
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Appendix A – Pairwise Comparison Charts 
 
Table 9 - Pairwise Comparison Chart Primary Objectives 
 Reproducible 
Easy to 
Use 
Easy cell 
sheet 
removal 
Throughput 
(>1 sheet) 
Automated 
Nutrient 
Exchange 
Total Weight 
Reproducible X 1 1 1 1 4 .40 
Easy to use 0 X 0 0 0.5 0.5 .05 
Easy cell 
sheet removal 
0 1 X 0 1 2 .20 
Throughput 
(>1 sheet) 
0 1 1 X 1 3 .30 
Automated 
Nutrient 
Exchange 
0 0.5 0 0 X .5 .05 
 
 
Table 10 - Pairwise Comparison Chart Sub-objective: Reproducible 
Reproducible 
Mechanical 
Properties 
Sheet 
Dimensions 
Total Weight 
Mechanical 
Properties 
X 1 1 .67 
Sheet 
Dimensions 
0 X 0 .33 
 
 
 
56 
 
Table 11 - Pairwise Comparison Chart Sub-objective: Throughput 
 
Table 12 - Pairwise Comparison Chart Sub-objective: Easy Cell Sheet Removal 
 
 
 
 
 
 
 
 
 
Throughput 
Separate 
Chambers 
Template 
Material 
No Longer 
Present 
Generates 
Multiple 
Sheet  
Layers Have 
Attached/Aligned 
Total Weight 
Separate 
Chambers 
X 0 0 0 0 .11 
Template 
Material No 
Longer Present 
1 X 1 1 3 .44 
Generates 
Multiple Sheet  
1 0 X 0 1 .22 
Layers Have 
Attached/Aligned 
1 0 1 X 2 .33 
Easy Cell 
Sheet 
Removal 
Handling Packaging 
Removal 
from 
Bioreactor 
Total Weight 
Handling X 1 0.5 1.5 .42 
Packaging 0 X 0 0 .17 
Removal 
from 
Bioreactor 
0.5 1 X 1.5 .42 
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Table 13 - Pairwise Comparison Chart Sub-objective: Easy to Use 
 
 
 
 
 
 
 
Easy to Use 
Easy to 
Maintain 
Easy to 
Monitor 
Easy to 
Assemble 
Total Weight 
Easy to 
Maintain 
X 0 
 
0.5 0.5 .17 
Easy to 
Monitor 
1 X 
 
1 2 .67 
Easy to 
Assemble 
0.5 0 X 0.5 .17 
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Appendix B – Fibrin Hydrogel Methods 
Fibrin Gel Protocol 
Fibrinogen stock solution and Thrombin stock solutions were prepared separately and mixed to create a 
fibrin gel. 
Fibrinogen Stock (Sigma F 4753) 
Materials: 
 Sterile  H2O  
 HBSS buffer (20 mM Hepes, 0.9% NaCl) 
 Bovine Fibrinogen Type IV (Sigma F4753) 
Procedure: 
 Dissolve 250 mg fibrinogen in 7.5 ml HBSS 
 Warm to 37C in H2O to aid dissolution 
 Shake every 10 minutes until completely dissolved (about 1 hour) 
 Filter through syringe filter 
 Aliquot into 1.5ml aliquots (5 aliquots) [final conc=30mg/ml] 
HBSS 
Volume Hepes (g) diH2O (mL) NaCl (g) 
0.25 1.193 250 2.25 
0.5 2.383 500 4.5 
1 4.766 1000 9 
 
Thrombin Stock Solution (Sigma F4648) 
Materials: 
 HBSS buffer (20 mM Hepes, 0.9% NaCl) 
 Bovine Thrombin (Sigma F4648) 
 Sterile H2O  
 
Procedure: 
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 Calculate the number of units: # mg solid *(# NIH units/mg solid)=# units per bottle 
 Determine amount of liquid needed to reach 25 U/ml 
 The liquid added is 10 % diH2O and 90% HBSS 
 Dissolve thrombin in H2O and HBSS 
 Filter through syringe filter 
 Freeze in aliquots of 125 µl 
Volume Hepes (g) diH2O (mL) NaCl (g) 
0.25 1.192 250 2.25 
0.5 2.383 500 4.5 
1 4.766 1000 9 
 
Example: 
9 mg solid* (106NIH units/ mg solid) =954 units per bottle 
(954 units)/ (25 units/ml) =38.16 ml 
3.82 ml H2O+34.34 ml HBSS= 38.16 ml 
Final amounts:  
9 mg solid +3.82 ml diH2O +34.34 ml HBSS 
Fibrin Gel for use of Flexcell 
Materials: 
 Thrombin aliquot  
 Fibrinogen aliquot (3.8 mg/ ml)  
 20 mM HEPES in 0.9 % NACL saline solution (HBSS)  
 DMEM 1x media 
 2N Ca
++
 
 Cell Culture Media(FBS +1% P/S =1x DMEM) 
 Fibroblasts 
 Growth Media 
 Flexcell Tissue Train 6 well plates 
Procedure: 
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The final solution to make fibrin gels (25mm diameter) consists of 2/3 fibrinogen solution, 1/6 cell 
solution, and 1/6 thrombin solution, with the thrombin always being added last.  The final 
concentrations should be calculated on using 1.5 mL of combined solution if you are making hemisphere 
gels. 
 Fibrinogen: 
 Add fibrinogen aliquot (1.5 ML) to 7.5 mL of HBSS.  The concentration is now 5 mg/mL   
 Separate fibrinogen aliquots into desired amount of containers 
 For one aliquot it is easier to divide the 9mL of this solution into 3 containers each having 3mL. 
Cell Suspension: 
 Spin down cells in centrifuge for 10 minutes @ 1200 rpm. 
 Resuspend cells in enough cell culture media (DMEM + 10 % FBS) to give desired final 
concentration. 
 Once desired concentration is achieved, add amount of cell suspension to each fibrinogen 
container 
 Place containers on ice 
 For one aliquot of fibrinogen and thrombin 0.67mL of calls should be added to each container 
(To keep 4:1:1 ratio) 
 
Thrombin 
 Add 2mL of DMEM w/o FBS or BCS (just use 1x here) and 7.5µL of 2N Ca++ to 100 µL aliquot of 
thrombin.  Put on ice. 
Gel Preparation 
 Take the container of the fibrinogen and call suspension and add amount of thrombin needed 
(0.67 mL for one aliquot of each).  Mix the suspension.   
 Quickly place 3 ml of the total solution in the center of the Flexcell plate. 
 4 gels can be made with the amount of volume of one container.  (If only one aliquot of each is 
used.   
 Repeat steps 3-5 in Gel Preparation until all of the containers are used.
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Appendix C - Burst Test Method 
Thickness, failure tension, failure strain and ultimate tensile strength (UTS) can be determined 
with this test.    The tissue sheets will be exposed to ddH2O for one hour to lyse the cells and 
equilibrated in PBS.    This eliminated the natural tension of the fibroblasts but does not decellularize the 
matrix.   The samples are placed in a tissue inflation device with a 1 cm diameter opening.   The samples 
are inflated with PBS at a rate of 1 ml/min to form an approximate spherical cap before failing.    The 
increasing pressure is measured with a pressure transducer and the displacement of the center of the 
cap is measured with a laser displacement system.    The thicknesses of the samples are measured using 
the laser displacement system before being inflated.   (Ahlfors, 2007) 
 The results will be analyzed using the following equations: (Ahlfors, 2007) 
Law of Laplace for a spherical cap: Maximum membrane tension T (N/m): 
T= 1/2PR 
where P (kPa) is the pressure when the tissue bursts and R (mm) is the corresponding radius at point of 
rupture. 
Radius of curvature R: 
R= (w2+a2)/2w 
where a (mm) is the radius of the clamp and w (mm) is the displacement at the center of the sample at 
failure. 
UTS = T/t 
where t is the initial thickness before inflation 
Extensibility is defined as Green’s stress at failure: 
E=1/2(failure
2 - 1) 
where failure is the stretch ratio as the sample fails. 
For a spherical cap the average stretch ratio along a meridian can be estimated using the radius of 
curvature: 
 =(R arcsin(a/R))/a 
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Appendix D – Bill of Materials 
 
 
 
         
         
         
         
         
         
         
         
 
        
         
         
         
         
         
         
          
 
